Helius Medical Tech Q2 2024 GAAP EPS $(0.64) Misses $(0.50) Estimate, Sales $182.000K Beat $150.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Helius Medical Tech (NASDAQ:HSDT) reported Q2 2024 GAAP EPS of $(0.64), missing the $(0.50) estimate by 28%. However, sales of $182.000K beat the $150.000K estimate by 21.33%, despite a 28.91% decrease from the same period last year.
August 12, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Helius Medical Tech reported a Q2 2024 GAAP EPS of $(0.64), missing the $(0.50) estimate by 28%. However, sales of $182.000K beat the $150.000K estimate by 21.33%, despite a 28.91% decrease from the same period last year.
The mixed earnings report for Helius Medical Tech shows a significant EPS miss but a notable sales beat. The EPS miss may concern investors, but the sales beat could provide some optimism. The overall impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100